Stock BMEA BIOMEA FUSION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
4.14 USD -63.27% Intraday chart for Biomea Fusion, Inc. -60.65% -71.49%
Jun. 07 Sector Update: Health Care Stocks Higher Late Afternoon MT
Jun. 07 Top Midday Decliners MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Higher Late Afternoon
Top Midday Decliners
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
Aktien New York Ausblick: Dow nach Arbeitsmarktdaten im Minus erwartet
Top Premarket Decliners
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold
U.S. FDA places hold on Biomea's diabetes trial
Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold
Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biomea Fusion Shares Decline Following JPMorgan Downgrade
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219
Biomea Fusion, Inc. Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes
Biomea Fusion Says Long-Term Data Show Improved Glycemic Control in Phase 2 Trial of BMF-219 to Treat Diabetes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMEA Stock
  4. News Biomea Fusion, Inc.
  5. Other languages